Please take a moment to review the latest ASCO News
- Nearly All Oncology Providers Report Prior Authorization Causing Delayed Care, Other Patient Harms
- Updated Position Statement on Drug Repository Programs Aims to Increase Access to Treatment Through Open Distribution Systems
- AMA House of Delegates Approves ASCO-Backed Resolutions on Fertility Preservation, American-Manufactured Personal Protective Equipment, and Third-Party Pharmacy Benefit Administrators
- FDA Grants Accelerated Approval to Mirvetuximab Soravtansine-gynx for FRĪ± Positive, Platinum-resistant Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
- Uniting on Shared Priorities to Improve Cancer Care: ASCO and ECO Formalize Collaboration with a Memorandum of Understanding
- FDA Approves Tremelimumab in Combination with Durvalumab and Platinum-based Chemotherapy for Metastatic Non-small Cell Lung Cancer
- FDA Approves Brentuximab Vedotin in Combination with Chemotherapy for Pediatric Patients with Classical Hodgkin Lymphoma
- FDA Approves Cemiplimab-rwlc in Combination with Platinum-based Chemotherapy for Non-small Cell Lung Cancer
- CMS Moves to Diminish Medicare Coverage Delays, Barriers to Access, Following ASCO Comments
- 2023 Medicare Reimbursement Cuts, MIPS Value Pathways, ASP +6% for 340B Finalized
- Urge Lawmakers to Address Up to 10% Medicare Reimbursement Cut
- Urge Lawmakers to Address Up to 10% Medicare Reimbursement Cut
- COVID-19 Public Health Emergency Extended Through Mid-January 2023
- COVID-19 Public Health Emergency Extended Through Mid-January 2023
- AACR and ASCO Release Joint Policy Statement on Electronic Nicotine Delivery Systems